Evidence map›Paper›PMID 37464232›Full record

ArticleVirchows Archiv : an international journal of pathology2023

Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma.

Hideaki Hirai, Masato Nakaguro, Yuichiro Tada, Natsuki Saigusa, Daisuke Kawakita, Yoshitaka Honma, Satoshi Kano, Kiyoaki Tsukahara, Hiroyuki Ozawa, Takuro Okada and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 15 institutions in 1 country.

Hideaki Hirai *Department of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 160-0023, Japan.
Masato Nakaguro *Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.ORCID http://orcid.org/0000-0001-6987-3043
Yuichiro Tada *Department of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0159-8660
Natsuki Saigusa *Department of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 160-0023, Japan.
Daisuke KawakitaDepartment of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID http://orcid.org/0000-0003-3794-2790
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Satoshi KanoDepartment of Otolaryngology Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Hiroyuki OzawaDepartment of Otorhinolaryngology Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Takuro OkadaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan.
Kenji OkamiDepartment of Otolaryngology Head and Neck Surgery, Tokai University School of Medicine, Isehara, Japan.
Keisuke YamazakiDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Yukiko SatoDepartment of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Makoto UranoDepartment of Diagnostic Pathology, Fujita Health University Bantane Hospital, Nagoya, Japan.
Manami KajiwaraDepartment of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 160-0023, Japan.
Yoshitaka UtsumiDepartment of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 160-0023, Japan.
Tomotaka ShimuraDepartment of Otolaryngology, Showa University Fujigaoka Hospital, Yokohama, Japan.
Chihiro FushimiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
Akira ShimizuDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Takahito KondoDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan.
Yorihisa ImanishiDepartment of Otorhinolaryngology, Head and Neck Surgery, International University of Health and Welfare, Narita Hospital, Narita, Japan.
Akihiro SakaiDepartment of Otolaryngology Head and Neck Surgery, Tokai University School of Medicine, Isehara, Japan.
Yuichiro SatoDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Takafumi TogashiDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Toyoyuki HanazawaDepartment of Otolaryngology, Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Takashi MatsukiDepartment of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Kazuto YamazakiDepartment of Surgical Pathology, Teikyo University, Chiba Medical Center, Ichihara, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-Ku, Tokyo, 160-0023, Japan. nagao-t@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0003-2075-9738
Tokyo Medical University · JPNiigata Cancer Center Hospital · JPMita Hospital · JPTokai University · JPTokyo Medical University Hachioji Medical Center · JPChiba University · JPFujita Health University · JPHokkaido University · JPInternational University of Health and Welfare · JPKeio University · JPKitasato University · JPNagoya City University · JPNagoya University Hospital · JPNational Cancer Center Hospital East · JPShowa University Fujigaoka Hospital · JP

Funding

Japan Society for the Promotion of Science 19K165681Japan Society for the Promotion of Science 20K07417Japan Society for the Promotion of Science 20K07597Japan Society for the Promotion of Science 21K09616Japan Society for the Promotion of Science 21K16835Japan Society for the Promotion of Science 22K06939Japan Society for the Promotion of Science 22K06969Japan Society for the Promotion of Science 23K06432
6 · The paper itself

Abstract

Salivary duct carcinoma (SDC) is an aggressive type of salivary gland carcinoma. Recently, immunotherapies targeting immune checkpoints, including PD1, PD-L1, CTLA4, and LAG3, have had a considerable prognostic impact on various malignant tumors. The implementation of such immune checkpoint inhibitor (ICI) therapies has also been attempted in cases of salivary gland carcinoma. The tumor immune microenvironment (TIME) is implicated in tumorigenesis and tumor progression and is closely associated with the response to ICI therapies. However, the TIME in SDC has not been fully explored. We examined the immunohistochemical expression of CD8, FOXP3, PD1, PD-L1, CTLA4, LAG3, and mismatch repair (MMR) proteins, tumor-infiltrating lymphocytes (TILs), and microsatellite instability (MSI) status in 175 cases of SDC. The associations between these TIME-related markers and the clinicopathological factors and prognosis were evaluated. An elevated expression of CD8, FOXP3, PD1, CTLA4, and LAG3 was associated with more aggressive histological features and an advanced N and/or M classification, elevated Ki-67 index, and poor prognosis. Furthermore, cases with a high PD-L1 expression exhibited more aggressive histological features and adverse clinical outcomes than those with a low expression. Alternatively, there was no significant correlation between TILs and clinicopathological factors. No SDC cases with an MSI-high status or MMR deficiency were found. The coexistence of both an immunostimulatory and immunosuppressive TIME in aggressive SDC might play a role in the presence of T-cell exhaustion. The contribution of multiple immune escape pathways, including regulatory T cells and immune checkpoints, may provide a rationale for ICI therapy, including combined PD1/CTLA4 blockade therapy.

Indexed as

CarcinomaSalivary Gland NeoplasmsB7-H1 AntigenCTLA-4 AntigenForkhead Transcription FactorsHumansLymphocytes, Tumor-InfiltratingMicrosatellite InstabilityPrognosisSalivary DuctsTumor MicroenvironmentB7-H1 AntigenCTLA-4 AntigenForkhead Transcription FactorsImmune microenvironmentPD-L1PrognosisSalivary duct carcinomaSalivary gland tumor

Identifiers

PMID37464232
OpenAlexW4384664634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.